Sun Pharma is expected to post moderate revenue growth in Q2FY26, led by steady US and specialty sales, though profit margins could narrow amid pressure in the India business and lower Revlimid contribution.
Sun Pharma is expected to post moderate revenue growth in Q2FY26, led by steady US and specialty sales, though profit margins could narrow amid pressure in the India business and lower Revlimid contribution.